Clinical trial
Maraviroc in Rheumatoid Arthritis
NCT00427934 · Pfizer, Industry · Terminated
Key facts
| NCT number | NCT00427934 |
|---|---|
| Title | Maraviroc in Rheumatoid Arthritis |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of Maraviroc in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate |
| Lead sponsor | Pfizer, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | Maraviroc, Maraviroc Placebo |
| Enrollment | 128 |
| Start date | Feb 1, 2007 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jan 29, 2007 |
| Last update posted | Nov 5, 2014 |
| Countries | Australia, Germany, India, Italy, Mexico, Portugal, Spain, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: